Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
|
|
EyePoint Pharmaceuticals, Inc. (EYPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K
| Investor presentation |
| 07/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/10/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 05/26/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 05/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc.",
"COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT is made as of May 17, 2023 , by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 480 Pleasant Street, Suite C-400, Watertown, MA 02472 , and Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005 . Capitalized terms used, but not otherwise defined, in this Agreement have the meanings assigned to them in the Product Rights Agreement . RECITALS Whereas, EyePoint owns the rights to, and has commercialized in the United States, YUTIQ® 0.18 mg , which was approved by the U.S. Food and Drug Administration for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye...",
"EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass., May 18, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® 0.18mg to Alimera Sciences, Inc. . YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment ..." |
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
SC 13G/A
| Cormorant Global Healthcare Master Fund, LP reports a 9.3% stake in EyePoint Pharmaceuticals, Inc. |
| 03/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 16.9% stake in EyePoint Pharmaceuticals, Inc. |
| 01/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ – State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 – WATERTOWN, Mass, January 23, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has entered into a lease agreement to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTI..." |
|
| 01/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/06/2023 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...|
Docs:
|
"FIRST amendment to employment agreement",
"FIRST amendment to employment LETTER agreement",
"Recitals WHEREAS, Employee serves as the Chief Financial Officer of the Company; WHEREAS, Employee has previously entered into an Employment Agreement with the Company, as amended to the date hereof ; and WHEREAS, the Company desires to enter into a new employment agreement with Employee to ensure that Employee is retained on a full-time basis in accordance with the terms and conditions set forth herein. Agreement NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and Employee hereby agree as follows: 1. Position, Duties and Place of Employment. Employee will be employed by the Company pursuant to this Agreemen...",
"Recitals WHEREAS, Employee serves as the Chief Commercial Officer of the Company; WHEREAS, Employee has previously entered into an Employment Agreement with the Company, as amended to the date hereof ; and WHEREAS, the Company desires to enter into a new employment agreement with Employee to ensure that Employee is retained on a full-time basis in accordance with the terms and conditions set forth herein. Agreement NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and Employee hereby agree as follows: 1. Position, Duties and Place of Employment. Employee will be employed by the Company pursuant to this Agreeme...",
"EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines – Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 – – Cash and investments of approximately $144 million as of December 31, 2022 – WATERTOWN, Mass, January 5, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901. EYP-1901 i...",
"EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer Dr. Duker has served as EyePoint’s Chief Operating Officer since November 2021 WATERTOWN, Mass., January 4, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., who has served as the company’s Chief Operating Officer since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker will also oversee regulatory affairs. “Jay has been a tremendous asset to our team since he joined as COO, and we look forward to continuing to ben..." |
|
| 11/16/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 10/11/2022 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 09/29/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|
|
|